Expert Speakers | 8th Neuropsychiatric Drug Development

Expert Speaker Faculty

Aaron Koenig - Chief Medical Officer at Delix Therapeutics, Neuropsychiatric Drug Development Conference

Aaron Koenig

Chief Medical Officer

Delix Therapeutics

Abhi Pratap - Executive Director, Global Evidence Lead, Neuropsychiatric Drug Development Summit

Abhishek Pratap

Executive Director, Global Evidence Lead

Boehringer Ingelheim

Alastair Brown - Senior vice president & head of translational science at Nxera Pharma, Neuropsychiatric Drug Development Conference

Alastair Brown

Senior Vice President, Translational Medicine

Nxera Pharma

Alex Goddard - Director, McQuade Center for Strategic Research and Development at Otsuka, Neuropsychiatric Drug Development Summit

Alex Goddard

Director, McQuade Center for Strategic Research and Development

Otsuka

Allison House Gecewicz - Senior Vice President & Head of Clinical Operations of Cybin, Neuropsychiatric Drug Development Summit

Allison House-Gecewicz

Senior Vice President & Head of Clinical Operations

Cybin

Amy Kruse - Chief Investment Officer at Satori Capital, Neuropsychiatric & Psychedelic Drug Development Conference

Amy Kruse

Chief Investment Officer

Satori Capital

Chirs Weyrer - Principal at Vida Ventures, Neuropsychiatric & Psychedelic Drug Development Conference

Chris Weyrer

Principal

Vida Ventures

Christopher Ocampo - Group Medical Director, Psychiatry of AbbVie, Neuropsychiatric Drug Development Summit

Christopher Ocampo

Group Medical Director, Psychiatry

Abbvie

Colin Sauder - Chief Scientific Officer at Karuna Therapeutics, Neuropsychiatric & Psychedelic Drug Development Summit

Colin Sauder

Chief Scientific Officer

Adams Clinical (formerly Bristol Myers Squibb / Karuna Therapeutics)

Dan Bonner -Co-Founder & Senior Vice President at Seaport Therapeutics, Neuropsychiatric & Psychedelic Drug Development Summit

Dan Bonner

Co-Founder & Senior Vice President, Platform

Seaport Therapeutics

David Olson - Chief Innovation Officer at Delix Therapeutics, Neuropsychiatric & Psychedelic Drug Development Conference

David Olson

Chief Innovation Officer

Delix Therapeutics

David Ruhl- Principal Scientist, Translational Science of Neurocrine Bioscience, Neuropsychiatric Drug Development Summit

David Ruhl

Principal Scientist, Translational Science

Neurocrine Biosciences

Drew Elias - Director, Global Regulatory Lead of Neuroscience at Johnson & Johnson, Neuropsychiatric Drug Development Forum

Drew Elias

Director, Global Regulatory Lead, Neuroscience

Johnson & Johnson

Heramb Chadchankar - Senior director & head of translational science at Kynexis Therapeutics, Neuroscience and Psychedelic Drug Development Conference

Heramb Chadchankar

Senior Director & Head of Translational Science

Kynexis Therapeutics

Jackie Von Salm - Co-Founder & Chief Scientific Officer at Psilera, Neuropsychiatric Drug Development Forum

Jackie von Salm

Co-Founder & Chief Scientific Officer

Psilera

Jacob Jacobsen - Chief Executive Officer of Evecxia Therapeutics, Neuropsychiatric Drug Development Conference

Jacob Jacobsen

Chief Executive Officer

Evecxia Therapeutics

James Cronican - Head of Translational Medicine & Clinical Pharmacology for Neuroscience & Mental Health at Boehringer Ingelheim, Neuropsychiatric Drug Development Forum

James Cronican

Head of Translational Medicine & Clinical Pharmacology Neuroscience & Mental Health

Boehringer Ingelheim

James Gilligan - President & Chief Executive Officer at Tryp Therapeutics, Neuropsychiatric & Psychedelic Drug Development Forum

James Gilligan

President & Chief Executive Officer

Tryp Therapeutics

Jamileh Jemison - Medical Director of Clinical Development at MindMed, Neuropsychiatric Drug Development Conference

Jamileh Jemison

Medical Director, Clinical Development

MindMed

Janet Nicholson - Global Asset Lead, CNS Diseases, Translational Medicine at Boehringer Ingelheim, Neuropsychiatric & Psychedelic Drug Development Forum

Janet Nicholson

Global Asset Lead - CNS Diseases & Translational Medicine

Boehringer Ingelheim

Jessica Ash - Director of Digital Health & Research at Otsuka, Neuropsychiatric & Psychedelic Drug Development Forum

Jessica Ash

Director of Digital Health, R&D

Otsuka

Johan Luthman - Executive Vice President & Head of Research at Lundbeck, Neuropsychiatric & Psychedelic Drug Development Conference

Johan Luthman

Executive Vice President & Head of R&D

Lundbeck

Jonathan Nassi - Senior Director Translational Science & Head of Discovery Lab at Inscopix, Neuropsychiatric Drug Development Conference

Jonathan Nassi

Senior Director & Head Of The Discovery Lab

Inscopix

Kevin Spencer - Associate Professor of Psychiatry at Harvard University, Neuropsychiatric & Psychedelic Drug Development Summit

Kevin Spencer

Associate Professor of Psychiatry

Harvard University

Krishna Vadodaria - Director at Engrail Therapeutics, Neuropsychiatric & Psychedelic Drug Development Summit

Krishna Vadodaria

Director

Engrail Therapeutics

Liam Scott - Senior Director of Translational Sciences at Neumora, Neuropsychiatric Drug Development Summit

Liam Scott

Senior Director

Neumora

Mark Pollack - Chief Medical Officer at Reunion Neuroscience, Neuropsychiatric Drug Development Summit

Mark Pollack

Chief Medical Officer

Reunion Neuroscience

Matt Harlin - Senior Director, Discovery Research, Early Phase & Translational Medicine at Otsuka, Neuropsychiatric Drug Development Summit

Matt Harlin

Senior Director - Discovery Research, Early Phase & Translational Medicine

Otsuka

Matt Harlin - Senior Group Leader at Harvard and MIT, Neuropsychiatric Drug Development Summit

Matthew Johnson

Senior Group Leader

The Broad Institute of MIT & Harvard

Matt Kuntz - Vice President & Global Head of Regulatory Affairs at AbbVie, Neuropsychiatric Drug Development Summit

Matthew Kuntz

Vice President, Global Regulatory Affairs, Neuroscience

Abbvie

Michael Bowen - Chief Scientific Officer of Kinoxis Therapeutics, Neuropsychiatric Drug Development Conference

Michael bowen

CSO

Kinoxis Therapeutics

Nanco Hefting - Chief Scientific Specialist, Neuropsychiatric Drug Development Summit

Nanco Hefting

Chief Specialist

Lundbeck

Natalie Sacks - Venture Partner at Novo Holdings, Neuropsychiatric Drug Development Conference

Natalie Sacks

Venture Partner

Novo Holdings

Nurulain Zaveri - President and Chief Scientific Officer of Astraea Therapeutics, Neuropsychiatric Drug Development Summit

Nurulain Zaveri

President and Chief Scientific Officer

Astraea Therapeutics

Odette Hauke - Regulatory Affairs Consultant for Neuropsychiatric Drug Development

Odette Hauke

Regulatory Affairs Consultant

Independent

Sam Benezra - Senior Scientist, Neural Circuits Group at Biogen, Neuropsychiatric & Psychedelic Drug Development

Sam Benezra

Senior Scientist, Neural Circuits Group

Biogen

Shobi Ahmed - Chief Executive Officer of Sama Therapeutics, Neuropsychiatric Drug Development Summit

Shobi Ahmed

Chief Executive Officer

Sama Therapeutics

Silke Miller - Scientist of Translational Sciences at Johnson & Johnson, Neuropsychiatric & Psychedelic Drug Development

Silke Miller

Distinguished Scientist - Translational Sciences

Johnson & Johnson

Snezana Milanovic - Senior Director of Clinical Development at Neumora, Neuropsychiatric & Psychedelic Drug Development

Snezana Milanovic

Senior Director, Clinical Development

Neumora

Steve Brennan -Chief Medical Officer at Karuna Therapeutics, Neuropsychiatric & Psychedelic Drug Development

Steve Brannan

Former Chief Medical Officer

Karuna Therapeutics

Steve Levine - Chief Patient Officer at Compass Pathways, Psychedelic Drug Development Conference

Steve Levine

Chief Patient Officer

Compass Pathways

Steve Hyman - Professor of Stem Cell & Regenerative Biology at Harvard University, Psychedelic Drug Development Conference

Steven Hyman

Professor of Stem Cell & Regenerative Biology

Harvard University

Suresh Durgam - Chief Medical Officer at Intra-Cellular Therapies, Psychedelic Drug Development Conference

Suresh Durgam

Chief Medical Officer, Executive Vice President

Intra-Cellular Therapies

Trent Fowler - Associate Director, Bioanlaysis, Genomics & Biomarker Research Early Phase Translational Medicine at Otsuka, Psychedelic Drug Development Summit

Trent Fowler

Associate Director

Otsuka

William Horan - Clinical Science Program Lead Neuropsychiatry at Bristol Myers Squibb, Psychedelic Drug Development Forum

William Horan

Clinical Science Program Lead, Neuropsychiatry

Bristol Myers Squibb

Zhanyan Fu - Associate Director of Broad Institute of MIT and Harvard, Neuroscience and Psychedelic Drug Development Conference

Zhanyan Fu

Associate Director

Broad Institute of MIT & Harvard

Explore the Agenda

Partner With Us